Bolt Therapeutics, Inc. (BOLT)

They are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Their proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that directly kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. Their lead product candidate BDC-1001 is a HER2 Boltbody ISAC comprised of a HER2-targeting biosimilar for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. They have demonstrated robust single agent anti-tumor activity in multiple preclinical models, including elimination of large tumors (~500 mm3), as well as tumors that are refractory to trastuzumab or ado-trastuzumab emtansine. In their preclinical safety studies, BDC-1001 was well tolerated and no adverse safety signals were observed. They believe these findings are encouraging for the therapeutic potential of BDC-1001. They initiated a Phase 1/2 trial of BDC-1001 in the first quarter of 2020 for the treatment of patients with HER2-expressing solid tumors. They are currently in the dose escalation portion of the trial and expect to move into Phase 2 dose expansions in key solid tumor indications with unmet medical need in 2021.

Industry
Pharmaceuticals

CEO	CFO
Randall C. Schatzman	William P. Quinn

Randall C. Schatzman, Ph.D. has served as our Chief Executive Officer and director since July 2019. From 2004 to March 2018, Dr. Schatzman served as President, Chief Executive Officer and a member of the board of directors of Alder BioPharmaceuticals, Inc. From 1999 to 2004, Dr. Schatzman served as Senior Vice President of Discovery Research at Celltech R&D, Inc., a wholly-owned subsidiary of Celltech Group plc. From 1995 to 1999, Dr. Schatzman served as Director of Gene Discovery at Mercator Genetics Inc. From 1987 to 1995, Dr. Schatzman served as Section Leader at Roche Bioscience, previously Syntex Corp., a subsidiary of Roche Holdings Ltd. Dr. Schatzman holds a Ph.D. in Molecular Pharmacology from Emory University and a B.S. in Biochemistry from Purdue University. We believe that Dr. Schatzman is qualified to serve on our board of directors due to his daily insight into corporate matters as our Chief Executive Officer and his extensive background in the biotechnology industry.

William P. Quinn has served as our Chief Financial Officer since May 2020. From November 2017 to May 2020, Mr. Quinn served as Chief Financial Officer and Senior Vice President, Finance and Corporate Development, of Sunesis Pharmaceuticals, Inc. From 2011 to November 2017, Mr. Quinn served as President and Chief Executive Officer of Bullet Biotechnology, Inc. From 2003 to 2011, Mr. Quinn served in various positions at Jazz Pharmaceuticals, Inc. From 2001 to 2002, Mr. Quinn served as Chief Operating Officer and Chief Financial Officer at Novation Biosciences. From 1999 to 2001, Mr. Quinn served as Associate Partner at Mobius Venture Capital, an early-stage venture capital fund. Since 2011, Mr. Quinn has served on the board of directors of A Foundation Building Strength, a non-profit dedicated to finding treatments for Nemaline Myopathy. Mr. Quinn holds a B.A. and M.A. from Stanford University and an M.B.A. from Stanford Graduate School of Business.

Employees	Founded
63	2015

Address: 900 Chesapeake Drive Redwood City, California 94063

Telephone: (650) 665-9295

Web page: http://www.boltbio.com

Expected Date	2/5/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	$16.00-$18.00

Share prices ($)

What do you think will happen with the BOLT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Morgan Stanley

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Morgan Stanley/ SVB Leerink/ Stifel/ Guggenheim Securities
CO-Managers